Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in its stock price, attributed to alleged violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit was filed by Bleichmar Fonti & Auld LLP on behalf of investors, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 2, 2026, to request to lead the case in the U.S. District Court for the District of Maryland [4]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [7]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [7]. Group 3: Stock Price Impact - Following the announcement of poor financial results on September 25, 2025, CarMax's stock price fell by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [8]. - The unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 outlook, led to an additional stock price drop of over 24% [8]. Group 4: Company Operations - CarMax's management had previously emphasized strong demand for its vehicles, which was later alleged to have been artificially boosted by pre-tariff purchases [5]. - The law firm is also investigating whether CarMax adequately assessed its portfolio of car loans following the CEO's departure [6].

ETH is only expensive relative to Revenue related metrics.By other narratives it is worth more.https://t.co/o03rpdISz9Ki Young Ju (@ki_young_ju):10 out of 12 Ethereum valuation models say ETH is undervalued. https://t.co/ng0FbHnPoT ...

Inside The Deal That Made Polymarket’s Founder One Of The Youngest Billionaires On Earth https://t.co/qnXSV3bTnY https://t.co/1qzI7S8XQp ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][4][6]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses and differentiation from competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

JHX LAWSUIT: BFA Law Reminds James Hardie Industries plc Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 23 DeadlineNovember 30, 2025 7:45 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company's senior executives for securities ...

RT Real Vision (@RealVision)🔥 Save $500 on your ticket with our Black Friday deal.Expires at midnight ⏰ ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 量化派 港股｜挂牌上市 据IPO早知道消息，量化派控股有限公司（以下简称"量化派"）于2025年11月27日正式以"2685"为 股票代码在港交所主板挂牌上市。 作为一家专注于中国消费领域的线上市场运营商，量化派持续深耕电商、汽车零售 O2O 等高频消费 场景，逐步构建起"用户—商品/服务—消费场景"的高效整合体系，为业务伙伴带来持续增长与协同 效应。 依托在消费领域的多年深耕，量化派沉淀了深厚的行业认知，并持续扩大用户与业务伙伴的覆盖范 围。截至 2025 年 5 月 31 日，量化派已连接超6,030万注册终端客户及2,646家业务伙伴，平台规 模稳步增长。 在业务规模不断扩大的同时，量化派的技术体系也持续深化——量化派自主研发的 "量星球" AI 技术 平台将运营、算法、营销等五大系统深度整合，为业务伙伴提供模块化、全链路的数字化解决方案， 助力提升获客效率、转化效果及整体运营能力。 在智能技术方面，量化派已构建起成熟的用户画像与分析体系，累计取得 9 项专利及 58 项软件著 作权，技术团 ...

2025 年 11 月 30 日 电力设备新能源、环保 储能产业链景气度延续，氢氨醇有望统筹、规模化、超前建设 ——电新环保行业周报 20251130 电力设备新能源 买入（维持） 环保 买入（维持） 作者 分析师：殷中枢 执业证书编号：S0930518040004 010-58452071 yinzs@ebscn.com 分析师：郝骞 执业证书编号：S0930520050001 021-52523827 haoqian@ebscn.com 分析师：陈无忌 执业证书编号：S0930522070001 021-52523693 chenwuji@ebscn.com 分析师：和霖 执业证书编号：S0930523070006 021-52523853 helin@ebscn.com 分析师：邓怡亮 执业证书编号：S0930525070003 021-52523802 dengyiliang@ebscn.com 要点 整体观点： 1、政策方面：国家发改委 11 月 27 日召开新闻发布会，在储能和氢能发展方面， 肯定储能、氢能的发展成效；后续推动储能获得合理收益，市场化是重要的调节手 段；而氢氨醇有望统筹、规模化、超 ...

证 券 研 究 报 告 华创交运公用|可控核聚变双周报（第 2 期） 我国启动聚变领域国际科学计划，核聚变项 推荐（维持） 目进展与技术研发稳步推进 1、顶层规划：11 月 24 日，中国科学院燃烧等离子体国际科学计划在合肥正 式启动，紧凑型聚变能实验装置 BEST 的研究计划也同步面向全球发布。本次 启动国际科学计划，既能强化我国超导托卡马克大科学团队的优势，也能凝聚 全球科学家的智慧与力量，共同突破聚变燃烧的前沿物理难题。 2、项目进展：11 月 25 日，国际热核聚变实验堆（ITER）项目近日迎来又一 关键节点，第五个真空室扇段（Sector Module #5）的吊装作业完成。ITER 作 为目前世界上规模最大、技术最复杂的聚变实验装置，有望为全球聚变能源迈 向工程化与产业化注入了强劲动力。如果保持当前节奏，ITER 有望在 2027 年 如期完成全部九个扇段的安装。 3、技术研发：11 月 26 日，根据 Nuclear Newswire 的报道，美国初创企业 Maritime Fusion 计划开发船载聚变反应堆，成为全球首家真正研究将托卡马克 装置安装在船上的公司。随着 IMO 2050 净零排 ...